title: New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
authors.affiliation: Munich Diabetes Research Group e.V. at the Munich Helmholtz Centre, Munich-Neuherberg, Germany eberhard.standl@lrz.uni-muenchen.de.
authors.forename: Eberhard
authors.initials: E
authors.lastname: Standl
authors.affiliation: Diabetes Research Group, Institute of Life Sciences, College of Medicine, Swansea University, Swansea, Wales, U.K.
authors.forename: David R
authors.initials: DR
authors.lastname: Owen
mesh_terms: D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016527:Drug Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D000069057:Insulin Detemir / Q000191:economics / Q000627:therapeutic use; D000069036:Insulin Glargine / Q000191:economics / Q000627:therapeutic use; D061268:Insulin Lispro / Q000191:economics / Q000627:therapeutic use; D049528:Insulin, Long-Acting / Q000191:economics / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000191:economics / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; C039441:insulin, polyethylene glycol(B1)-; D000069036:Insulin Glargine; D011092:Polyethylene Glycols; D000069057:Insulin Detemir; C571886:insulin degludec